Heart in Diabetes

Heart in Diabetes

Source: Healio interview
Disclosures: Handelsman is a co-chair of the Heart in Diabetes CME Conference.
September 09, 2021
3 min read

Hybrid Heart in Diabetes conference highlights intersection of cardiometabolic specialties

Source: Healio interview
Disclosures: Handelsman is a co-chair of the Heart in Diabetes CME Conference.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Leading experts from multiple specialties will once again convene to address the relationship between type 2 diabetes, cardiovascular and renal disease along with the latest research demonstrating their interconnectedness.

The fifth annual Heart in Diabetes CME Conference, described as where the heart, kidney and diabetes meet in clinical practice, will take place Friday through Sunday at the Sheraton New York Times Square Hotel in New York City. This year the 3-day conference will be hybrid, combining live in-person and live-online sessions, followed by 90 days of on-demand access.

Source: Adobe Stock

The conference is structured to help clinicians improve care for patients with diabetes, CVD, chronic kidney disease, heart failure and related conditions by distilling the latest trial data and their relevance across the specialties. The disorders share many pathologic features and often occur in the same person, but until recently were treated as separate conditions, according to conference co-chair Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE.

Yehuda Handelsman

“This is the only place where each of the cardiometabolic specialties has equal input and an equal seat at the table,” Handelsman, also medical director and principal investigator of the Metabolic Institute of America in Tarzana, California and an Endocrine Today Editorial Board Member, told Healio. “This is the only meeting where we look at prediabetes, diabetes, obesity syndrome and how those conditions relate to cardiovascular disease, heart failure, kidney disease and nonalcoholic fatty liver disease. How do we manage them; how do we coordinate the medications? SGLT2 inhibitors and GLP-1 receptor agonists, for example, are drugs for cardiologists, endocrinologists, nephrologists and primary care providers. Each provider needs to use these drugs differently. This is the space where we put these ideas together.”

The conference, initially organized as a 2-day event, has expanded to meet a fast-growing need, Handelsman said.

“Now, there is so much information, and now we also have COVID-19,” Handelsman said. “We are probably the only meeting looking at, for example, the role of both a mineralocorticoid antagonist or an SGLT2 inhibitor in the prevention and management of COVID-19.”

Attendees can earn up to 26.25 CME and ABIM credit points during the conference, with all sessions available for 90 days after the program concludes, Handelsman said.

Conference highlights include the following:

  • On Friday at 10 a.m., Christopher Wilcox, MD, PhD, Biykem Bozkurt, MD, PhD, and conference co-chair Mikhail Kosiborod, MD, will lead presentations on cardiometabolic treatments for COVID-19, including details on the recently presented DARE-19 trial.
  • On Friday at 1:20 p.m., Heart in Diabetes with Circulation will feature presentations on the effect of SGLT2 inhibition on atrial fibrillation with Stephen D. Wiviott, MD, body composition and risk for CVD in diabetes with Kershaw V. Patel, MD, and gestational diabetes and coronary artery calcium in women with Erica P. Gunderson, PhD.
  • Two debates during the meeting will focus on whether biomarkers or imaging are the best modality to predict CVD (featuring Brendan Everett, MD, and Norman Lepor, MD) and on whether brand new data should be rapidly adopted by guidelines (featuring Robert J. Chilton, DO, and Sanjay Kaul, MD).
  • A Sunday morning session on heart disease in women, beginning at 9:15 a.m., will include presentations on CVD and polycystic ovary syndrome “smoke vs. fire” with Andrea Dunaif, MD, the link between migraine and CVD with Gina P. Lundberg, MD, and the impact of sex hormones on heart failure in men and postmenopausal women with Erin D. Michos, MD.
  • The year’s “Luminary in Cardiometabolic Medicine” award will be presented Saturday to Robert H. Eckel, MD, who will also present the keynote talk about his professional journey in lipids, obesity, metabolic syndrome, diabetes and the heart.

New this year, every day concludes with a 1-hour panel discussion with featured faculty discussing and responding to questions. The meeting will also feature abstract presentations from scientists and researchers around the world, as well as several non-CME, industry-supported presentations. Abstracts will be published in the American Heart Journal.

The Cardiology Today, Endocrine Today and Healio staffs will provide coverage from the Heart in Diabetes CME Conference, including reports on the sessions, debates and much more. For more information on the Heart in Diabetes conference and registration, visit www.heartindiabetes.com.